| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c739f455bec3f12bcf44d71de1b4aada |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4808
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2077
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-606 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-606
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 |
| filingDate |
2018-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2020-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ed2829e74c8d3cc1bcb5b0b22ce275b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_194db54896351b165daae75fcdc1a6a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b60800746226f48ea1b831207a76633c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25bbfc760e0c7f9a500e7a5de177fcf2 |
| publicationDate |
2020-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10555907-B2 |
| titleOfInvention |
Controlled-release solid dosage forms of mesalamine |
| abstract |
Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023150345-A1 |
| priorityDate |
2012-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |